Retrosense, a life sciences spinout from Wayne State University, has secured $6m in its series B.
The Michigan-based firm raised a $7m series A earlier in 2015, bringing its total raised to $13m. Existing backer BlueWater Angel as well as new investors RBV Capital, ExSight Capital, and Santen Pharmaceutical all participated in the round.
Sean Ainsworth, CEO of RetroSense Therapeutics, said: “The follow-on participation from Series A investors, combined with new institutional investors in the Series B financing, demonstrates the great enthusiasm for RetroSense Therapeutics’ promise in ocular gene therapy. This syndicate of investors is tremendously strong in ophthalmology and optogenetics. Their financing and support will enable us to move forward more quickly, with broader reach.”
